Efficacy of poly-gamma-glutamic acid in women with high-risk human papillomavirus-positive vaginal intraepithelial neoplasia: An observational pilot study

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Poly-gamma-glutamic acid (γ-PGA) is a natural polymer that is synthesized by Bacillus species and has been reported to have antitumor activity. The aim of this study was to investigate the effect of γ-PGA on the treatment of vaginal intraepithelial neoplasia (VAIN). A retrospective observational study on γ-PGA therapy for biopsy-proven VAIN was conducted. The efficacy was assessed by evaluating the results of Pap cytology and the viral load of high-risk HPV at three time points: at enrollment, and at the first and second post-treatment visits. Of 17 patients treated with γ-PGA, only 12 patients who had a high-risk HPV infection were included in the analysis. Histology was VAIN1 in seven patients, VAIN2 in two patients, and VAIN3 in three patients. γ-PGA was administered for newly diagnosed VAIN in five (41.7%) patients and persistent VAIN in seven (58.3%) patients for the mean time of 4.5 months. At the first and second post-treatment visits, cytological regression was observed in five (41.7%) and six (50%) patients, respectively. Regarding the HPV load, the overall response rate was 66.7%, and the mean level was 670.6 ± 292.5 RLU at the first follow-up, which was lower than the initial viral load of 1,494.8 ± 434.5 RLU (p = 0.084). At the second follow-up, the overall response rate was 58.3%, and the mean viral load level was 924.2 ± 493.7 RLU. γ-PGA may be helpful for the cytological regression and reduction of viral load in patients with high-risk HPV-positive VAIN, suggesting that γ-PGA is a promising treatment option for primary or persistent VAIN.

Original languageEnglish
Pages (from-to)1163-1169
Number of pages7
JournalJournal of Microbiology and Biotechnology
Volume25
Issue number7
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Prostaglandins A
Observational Studies
Viral Load
Neoplasms
Therapeutics
poly(gamma-glutamic acid)
Bacillus
Cell Biology
Histology
Polymers
Retrospective Studies
Biopsy
Infection

Keywords

  • Human papillomavirus
  • Poly-γ-glutamic acid
  • Vaginal intraepithelial neoplasia

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

@article{64fd188f287143cd8db727be8218584c,
title = "Efficacy of poly-gamma-glutamic acid in women with high-risk human papillomavirus-positive vaginal intraepithelial neoplasia: An observational pilot study",
abstract = "Poly-gamma-glutamic acid (γ-PGA) is a natural polymer that is synthesized by Bacillus species and has been reported to have antitumor activity. The aim of this study was to investigate the effect of γ-PGA on the treatment of vaginal intraepithelial neoplasia (VAIN). A retrospective observational study on γ-PGA therapy for biopsy-proven VAIN was conducted. The efficacy was assessed by evaluating the results of Pap cytology and the viral load of high-risk HPV at three time points: at enrollment, and at the first and second post-treatment visits. Of 17 patients treated with γ-PGA, only 12 patients who had a high-risk HPV infection were included in the analysis. Histology was VAIN1 in seven patients, VAIN2 in two patients, and VAIN3 in three patients. γ-PGA was administered for newly diagnosed VAIN in five (41.7{\%}) patients and persistent VAIN in seven (58.3{\%}) patients for the mean time of 4.5 months. At the first and second post-treatment visits, cytological regression was observed in five (41.7{\%}) and six (50{\%}) patients, respectively. Regarding the HPV load, the overall response rate was 66.7{\%}, and the mean level was 670.6 ± 292.5 RLU at the first follow-up, which was lower than the initial viral load of 1,494.8 ± 434.5 RLU (p = 0.084). At the second follow-up, the overall response rate was 58.3{\%}, and the mean viral load level was 924.2 ± 493.7 RLU. γ-PGA may be helpful for the cytological regression and reduction of viral load in patients with high-risk HPV-positive VAIN, suggesting that γ-PGA is a promising treatment option for primary or persistent VAIN.",
keywords = "Human papillomavirus, Poly-γ-glutamic acid, Vaginal intraepithelial neoplasia",
author = "Koo, {Yu Jin} and Min, {Kyung Jin} and Jin-Hwa Hong and Lee, {Jae Kwan}",
year = "2015",
month = "1",
day = "1",
doi = "10.4014/jmb.1503.03106",
language = "English",
volume = "25",
pages = "1163--1169",
journal = "Journal of Microbiology and Biotechnology",
issn = "1017-7825",
publisher = "Korean Society for Microbiolog and Biotechnology",
number = "7",

}

TY - JOUR

T1 - Efficacy of poly-gamma-glutamic acid in women with high-risk human papillomavirus-positive vaginal intraepithelial neoplasia

T2 - An observational pilot study

AU - Koo, Yu Jin

AU - Min, Kyung Jin

AU - Hong, Jin-Hwa

AU - Lee, Jae Kwan

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Poly-gamma-glutamic acid (γ-PGA) is a natural polymer that is synthesized by Bacillus species and has been reported to have antitumor activity. The aim of this study was to investigate the effect of γ-PGA on the treatment of vaginal intraepithelial neoplasia (VAIN). A retrospective observational study on γ-PGA therapy for biopsy-proven VAIN was conducted. The efficacy was assessed by evaluating the results of Pap cytology and the viral load of high-risk HPV at three time points: at enrollment, and at the first and second post-treatment visits. Of 17 patients treated with γ-PGA, only 12 patients who had a high-risk HPV infection were included in the analysis. Histology was VAIN1 in seven patients, VAIN2 in two patients, and VAIN3 in three patients. γ-PGA was administered for newly diagnosed VAIN in five (41.7%) patients and persistent VAIN in seven (58.3%) patients for the mean time of 4.5 months. At the first and second post-treatment visits, cytological regression was observed in five (41.7%) and six (50%) patients, respectively. Regarding the HPV load, the overall response rate was 66.7%, and the mean level was 670.6 ± 292.5 RLU at the first follow-up, which was lower than the initial viral load of 1,494.8 ± 434.5 RLU (p = 0.084). At the second follow-up, the overall response rate was 58.3%, and the mean viral load level was 924.2 ± 493.7 RLU. γ-PGA may be helpful for the cytological regression and reduction of viral load in patients with high-risk HPV-positive VAIN, suggesting that γ-PGA is a promising treatment option for primary or persistent VAIN.

AB - Poly-gamma-glutamic acid (γ-PGA) is a natural polymer that is synthesized by Bacillus species and has been reported to have antitumor activity. The aim of this study was to investigate the effect of γ-PGA on the treatment of vaginal intraepithelial neoplasia (VAIN). A retrospective observational study on γ-PGA therapy for biopsy-proven VAIN was conducted. The efficacy was assessed by evaluating the results of Pap cytology and the viral load of high-risk HPV at three time points: at enrollment, and at the first and second post-treatment visits. Of 17 patients treated with γ-PGA, only 12 patients who had a high-risk HPV infection were included in the analysis. Histology was VAIN1 in seven patients, VAIN2 in two patients, and VAIN3 in three patients. γ-PGA was administered for newly diagnosed VAIN in five (41.7%) patients and persistent VAIN in seven (58.3%) patients for the mean time of 4.5 months. At the first and second post-treatment visits, cytological regression was observed in five (41.7%) and six (50%) patients, respectively. Regarding the HPV load, the overall response rate was 66.7%, and the mean level was 670.6 ± 292.5 RLU at the first follow-up, which was lower than the initial viral load of 1,494.8 ± 434.5 RLU (p = 0.084). At the second follow-up, the overall response rate was 58.3%, and the mean viral load level was 924.2 ± 493.7 RLU. γ-PGA may be helpful for the cytological regression and reduction of viral load in patients with high-risk HPV-positive VAIN, suggesting that γ-PGA is a promising treatment option for primary or persistent VAIN.

KW - Human papillomavirus

KW - Poly-γ-glutamic acid

KW - Vaginal intraepithelial neoplasia

UR - http://www.scopus.com/inward/record.url?scp=84937412208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937412208&partnerID=8YFLogxK

U2 - 10.4014/jmb.1503.03106

DO - 10.4014/jmb.1503.03106

M3 - Article

C2 - 25907060

AN - SCOPUS:84937412208

VL - 25

SP - 1163

EP - 1169

JO - Journal of Microbiology and Biotechnology

JF - Journal of Microbiology and Biotechnology

SN - 1017-7825

IS - 7

ER -